Int J Med Sci 2020; 17(10):1366-1374. doi:10.7150/ijms.45730
The prediction value of PI-RADS v2 score in high-grade Prostate Cancer: a multicenter retrospective study
1. Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
2. Department of Dermatology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
3. Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
4. Department of Urology, Xiangyang Central Hospital, Xiangyang, 441021, China.
#These authors contributed equally to this work.
Chen S, Yang Y, Peng T, Yu X, Deng H, Guo Z. The prediction value of PI-RADS v2 score in high-grade Prostate Cancer: a multicenter retrospective study. Int J Med Sci 2020; 17(10):1366-1374. doi:10.7150/ijms.45730. Available from http://www.medsci.org/v17p1366.htm
Background: To explore the prediction value of PI-RADS v2 in high-grade prostate cancer and establish a prediction model combined with related variables of prostate cancer.
Material and Methods: A total of 316 patients with newly discovered prostate cancer at Zhongnan Hospital of Wuhan University and Renmin Hospital of Wuhan University from December 2017 to August 2019 were enrolled in this study. The clinic information as age, tPSA, fPSA, prostate volume, Gleason score and PI-RADS v2 score have been collected. Univariate analysis was performed based on every variable to investigate the risk factors of high-grade prostate cancer. ROC curves were generated for the risk factors to distinguish the cut-off points. Logistic regression analyses were used to investigate the independent risk factors of high-grade prostate cancer. Nomogram prediction model was generated based on multivariate logistic regression analysis. The calibration curve, ROC curve, leave-one-out cross validation and independent external validation were performed to evaluate the discriminative ability, accuracy and stability of the nomogram prediction model.
Results: Of 316 patients, a total of 187 patients were diagnosed as high-grade prostate cancer. Univariate analysis showed tPSA, fPSA, prostate volume, PSAD and PI-RADS v2 score were significantly different between the high- and low-grade prostate cancer patients. Univariate and multivariate logistic regression analyses showed only tPSA, prostate volume and PI-RADS v2 score were the independent risk factors of high-grade prostate cancer. The nomogram could predict the probability of high-grade prostate cancer, with a sensitivity of 79.4% and a specificity of 77.6%. The calibration curve displayed good agreement of the predicted probability with the actual observed probability. AUC of the ROC curve was 0.840 (0.797-0.884). Leave-one-out cross validation indicated the nomogram prediction model could classify 81.4% cases accurately. External data validation was performed with a sensitivity of 80.6% and a specificity of 77.3%, the Kappa value was 0.5755.
Conclusions: PI-RADS v2 score had the value in predicting high-grade prostate cancer and the nomogram prediction model may help early diagnose the high risk prostate cancer.
Keywords: high-grade prostate cancer, PI-RADS v2, nomogram, prediction model